News
Calculating how breast cancers will respond to tamoxifen
MEDIA RELEASE:
08 Sep 2008
A discovery by Garvan scientists should help clinicians decide which women with breast cancer will make good candidates for anti-oestrogen therapies, such as tamoxifen, and which will not.
Three Garvan PhD students awarded Merck Sharp and Dohme scholarship
01 Sep 2008
Three outstanding Garvan PhD students are the joint recipients of Merck Sharp and Dohme’s 2008 Educational Scholarship, a sum of money awarded to a medical graduate undertaking a PhD at Garvan in bone or diabetes research.
New Australian Epigenome Alliance moves towards a Brave New World
MEDIA RELEASE:
22 Aug 2008
In the same week as the Australian Epigenome Alliance formed, Alliance member and Garvan epigenetics expert, Professor Susan Clark, was the Australian contributor to a Nature article about the global taskforce taking shape for the human epigenome project. According to Professor Clark, "we have the words, and now we need the syntax or grammar to make sense of them."
Where Science Meets Art
MEDIA RELEASE:
22 Aug 2008
Researchers at the Garvan Institute of Medical Research are used to challenges. So when invited to fuse their research with art and compete in Garvan’s in-house Science as Art project they were more than up to the challenge – and the results are surprising.
First step towards switching off breast cancer and leukaemia
MEDIA RELEASE:
08 Aug 2008
Garvan scientists have identified a way to ‘switch off’ a molecule, a key player in the molecular processes that trigger breast cancer and certain forms of leukaemia. The molecule, known as Gab2, operates downstream of a major breast cancer oncogene, HER2, the target of the drug Herceptin.
Research agreement to reveal secret lives of cells
MEDIA RELEASE:
06 Aug 2008
Garvan and CSIRO have signed a three-year collaboration agreement to investigate important cellular processes, including those impaired by diseases such as diabetes. They will be using a new computer vision system they developed jointly to watch intricate cellular processes in real time.
How molecules out of balance lead to human multiple myeloma and other cancers
MEDIA RELEASE:
29 Jul 2008
An international team of scientists, from Garvan, Harvard Medical School and the Max Planck Institute in Germany, has identified processes that are heavily implicated in human multiple myeloma and other B cell cancers, moving us closer to developing quick tests and readouts that could help in the tailored treatment of patients.
Glimpse the future of medical research at Garvan Open Day
MEDIA RELEASE:
18 Jul 2008
Garvan will open its doors on Sunday 17th August from 10am to 1pm for Open Day, giving the public the opportunity to meet and talk with leading scientists and learn about the future of science and medicine from some of the sharpest minds in Australia.
Potential to prevent loss of insulin in Type 2 diabetes
MEDIA RELEASE:
14 Jul 2008
Until now, it was thought that the processes leading to the death of insulin-secreting pancreatic cells were similar in both types of diabetes. Scientists at Garvan have now shown that the process is quite different in the two diseases. They have also identified a promising therapeutic target for people with Type 2 diabetes
Finding suggests novel ways to boost vaccination or natural defences
MEDIA RELEASE:
07 Jul 2008
Our bodies rely on the production of potent, or 'high affinity', antibodies to fight infection. The process is very complex, yet Garvan scientists have discovered that it hinges on a single molecule, a growth factor, without which it cannot function. This suggest ways to strengthen the body's natural defences.
